AG 1517__EGFR kinase inhibitor SCH 546738
Product Name
AG 1517
Description
EGFR kinase inhibitor
Purity
>98% (TLC)
CAS No.
153436-54-5
Molecular Formula
C16H14BrN3O2
Molecular Weight
360.2
Storage Temperature
-20ºC
Shipping Temperature
Shipped Ambient
Product Type
Inhibitor
Solubility
Soluble in DMSO
Source
Synthetic
Appearance
White to off-white solid
SMILES
COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Br)OC.Cl
InChI
InChI=1S/C16H14BrN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20)
InChIKey
LSPANGZZENHZNJ-UHFFFAOYSA-N
Safety Phrases
Classification:
Acute toxicity, Oral (Category 3)
Skin irritation (Category 2)
Serious eye damage (Category 1)
Specific target organ toxicity-single exposure (Category 3)
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes.
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection.
Hazard statements:
H301 Toxic if swallowed.
H315 Causes skin irritation.
H318 Causes serious eye damage.
H335 May cause respiratory irritation
Precautionary statements:
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P280 Wear protective gloves/ eye protection/ face protection.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/ physician.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
Cite This Product
AG 1517 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-427)
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19112033
Alternative Names
4-[(3-Bromophenyl)amino]-6,7-dimethoxyquinazoline hydrochloride, AG 1517, PD 153035, SU 5271, ZM 252868, PD 153,035, SU 5271, 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline
Research Areas
Cancer, Apoptosis, Cancer Growth Inhibitors, Cell Signaling, Tyrosine Kinase Inhibitors
PubChem ID
4705
Scientific Background
AG 1517 is a potent and selective ATP competitive inhibitor of the epidermal growth factor receptor tyrosine kinase EGFR.
References
1. Kunkel M.W., et al. (1996) Investigational New Drugs. 13(4): 295–302.
EGFR kinase inhibitor
Acute toxicity, Oral (Category 3)
Skin irritation (Category 2)
Serious eye damage (Category 1)
Specific target organ toxicity-single exposure (Category 3)
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes.
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection.
Hazard statements:
H301 Toxic if swallowed.
H315 Causes skin irritation.
H318 Causes serious eye damage.
H335 May cause respiratory irritation
Precautionary statements:
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P280 Wear protective gloves/ eye protection/ face protection.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/ physician.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.